EP1937300A4 - Méthodes et compositions pour produire et contrôler le profil effecteur de lymphocytes t par chargement et activation simultanés de sous-ensembles sélectionnés de cellules présentatrices d'antigène - Google Patents

Méthodes et compositions pour produire et contrôler le profil effecteur de lymphocytes t par chargement et activation simultanés de sous-ensembles sélectionnés de cellules présentatrices d'antigène

Info

Publication number
EP1937300A4
EP1937300A4 EP06801942A EP06801942A EP1937300A4 EP 1937300 A4 EP1937300 A4 EP 1937300A4 EP 06801942 A EP06801942 A EP 06801942A EP 06801942 A EP06801942 A EP 06801942A EP 1937300 A4 EP1937300 A4 EP 1937300A4
Authority
EP
European Patent Office
Prior art keywords
cells
activation
compositions
generate
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06801942A
Other languages
German (de)
English (en)
Other versions
EP1937300A2 (fr
Inventor
Lilin Wang
Dan Smith
Bill Phillips
Adrian Bot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Multicell Immunotherapeutics Inc
Original Assignee
Multicell Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multicell Immunotherapeutics Inc filed Critical Multicell Immunotherapeutics Inc
Publication of EP1937300A2 publication Critical patent/EP1937300A2/fr
Publication of EP1937300A4 publication Critical patent/EP1937300A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP06801942A 2005-08-17 2006-08-17 Méthodes et compositions pour produire et contrôler le profil effecteur de lymphocytes t par chargement et activation simultanés de sous-ensembles sélectionnés de cellules présentatrices d'antigène Withdrawn EP1937300A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70898005P 2005-08-17 2005-08-17
PCT/US2006/032512 WO2007022477A2 (fr) 2005-08-17 2006-08-17 Méthodes et compositions pour produire et contrôler le profil effecteur de lymphocytes t par chargement et activation simultanés de sous-ensembles sélectionnés de cellules présentatrices d'antigène

Publications (2)

Publication Number Publication Date
EP1937300A2 EP1937300A2 (fr) 2008-07-02
EP1937300A4 true EP1937300A4 (fr) 2009-08-12

Family

ID=37758473

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06801942A Withdrawn EP1937300A4 (fr) 2005-08-17 2006-08-17 Méthodes et compositions pour produire et contrôler le profil effecteur de lymphocytes t par chargement et activation simultanés de sous-ensembles sélectionnés de cellules présentatrices d'antigène

Country Status (2)

Country Link
EP (1) EP1937300A4 (fr)
WO (1) WO2007022477A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3042826A1 (fr) 2008-11-30 2010-06-03 Immusant, Inc. Compositions et procedes pour le traitement d'une maladie coeliaque
AU2014318889B2 (en) 2013-09-10 2020-02-20 Immusant, Inc. Dosage of a gluten peptide composition
EP3201354A1 (fr) 2014-09-29 2017-08-09 Immusant Inc. Utilisation de statut génétique hla pour évaluer ou sélectionner un traitement de la maladie c liaque
WO2016126611A1 (fr) 2015-02-02 2016-08-11 The University Of Birmingham Complexes d'épitope de peptide de fragment de ciblage ayant une pluralité d'épitopes de lymphocyte t
GB2576914A (en) * 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998036087A1 (fr) * 1997-02-13 1998-08-20 American National Red Cross Tolerance immunologique aux epitopes du hiv
WO2004027049A2 (fr) * 2002-09-20 2004-04-01 Astral, Inc. Procedes et compositions pour generer et controler le profil effecteur de lymphocytes t par le chargement et l'activation de sous-ensembles selectionnes de cellules presentant l'antigene

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6777546B2 (en) * 1997-10-07 2004-08-17 Loma Linda University Methods and substances for preventing and treating autoimmune disease
AU2001280934A1 (en) * 2000-07-28 2002-02-13 Alliance Pharmaceutical Corp. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
US6811785B2 (en) * 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998036087A1 (fr) * 1997-02-13 1998-08-20 American National Red Cross Tolerance immunologique aux epitopes du hiv
WO2004027049A2 (fr) * 2002-09-20 2004-04-01 Astral, Inc. Procedes et compositions pour generer et controler le profil effecteur de lymphocytes t par le chargement et l'activation de sous-ensembles selectionnes de cellules presentant l'antigene

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BELL JAMES J ET AL: "Asymmetric restoration of T cell tolerance revealed by an "in trans" EAE model", FASEB JOURNAL, vol. 18, no. 4-5, 2004, & FASEB MEETING ON EXPERIMENTAL BIOLOGY: TRANSLATING THE GENOME; WASHINGTON, DISTRICT OF COLUMBIA, USA; APRIL 17-21, 2004, pages Abst. 563.7 URL - http://ww, XP009119304, ISSN: 0892-6638 *
LEGGE K L ET AL: "Multi-modal antigen specific therapy for autoimmunity", INTERNATIONAL REVIEWS OF IMMUNOLOGY, HARWOOD ACADEMIC PUBLISHERS, LONDON, GB, vol. 20, 1 January 2001 (2001-01-01), pages 593 - 611, XP002970594, ISSN: 0883-0185 *
MELO MARCO E F ET AL: "Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases.", JOURNAL OF IMMUNOLOGY, vol. 168, no. 9, 1 May 2002 (2002-05-01), pages 4788 - 4795, XP002535132, ISSN: 0022-1767 *
PHILLIPS WILLIAM J ET AL: "Recombinant immunoglobulin-based epitope delivery: A novel class of autoimmune regulators", INTERNATIONAL REVIEWS OF IMMUNOLOGY, vol. 24, no. 5-6, September 2005 (2005-09-01), pages 501 - 517, XP009119306, ISSN: 0883-0185 *
ZAGHOUANI HABIB ET AL: "Contrasting efficacy of presentation by major histocompatibility complex class I and class II products when peptides are administered within a common protein carrier, self immunoglobulin", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 23, no. 11, 1993, pages 2746 - 2750, XP009119271, ISSN: 0014-2980 *
ZAMBIDIS E T ET AL: "EPITOPE-SPECIFIC TOLERANCE INDUCTION WITH AN ENGINEERED IMMUNOGLOBULIN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC., US, vol. 93, 1 May 1996 (1996-05-01), pages 5019 - 5024, XP002911069, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1937300A2 (fr) 2008-07-02
WO2007022477A3 (fr) 2007-08-30
WO2007022477A2 (fr) 2007-02-22

Similar Documents

Publication Publication Date Title
HUS1800021I1 (hu) Humán anti-Il-23 ellenanyagok, készítmények, eljárások és alkalmazások
HRP20190220T1 (hr) Anti-il-23 protutijela, pripravci, postupci i upotrebe
WO2009052125A9 (fr) Anticorps humains anti-amyloïdes, compositions, procédés et utilisations
WO2008133938A3 (fr) Intégration ciblée dans le locus ppp1r12c
EP2097534A4 (fr) Anticorps humains se liant à cd70 et utilisations de ceux-ci
EP2043687A4 (fr) Anticorps anti-amyloides, compositions, procedes et utilisations
LT2679676T (lt) Būdai ir organizmai, skirti nuo auginimo priklausomai 1,4-butandiolo gamybai
ZA200711073B (en) Anti-MCP-1 antibodies, compositions, methods and uses
ZA200904657B (en) Human antibodies that bind CD70 and uses thereof
PL2266420T3 (pl) Peletki białka roślinnego
EP1937300A4 (fr) Méthodes et compositions pour produire et contrôler le profil effecteur de lymphocytes t par chargement et activation simultanés de sous-ensembles sélectionnés de cellules présentatrices d'antigène
WO2009006359A8 (fr) Anticorps anti-mcp-1, compositions, procédés et utilisations
WO2008030909A3 (fr) Compositions et méthodes permettant de conférer une résistance aux odeurs à des articles et articles fabriqués à l'aide de ces compositions et de ces méthodes
EP2007409A4 (fr) Régulation de réponses immunitaires par modulation de la fonction de cellules présentant des antigènes
GB0509318D0 (en) TCR-independent activation of T cells
AU2005900390A0 (en) NKT cell activation and method and composition therefor
AU3442P (en) With Love Lavandula hybrid
AU2005900654A0 (en) Modified nutraceutical composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080317

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WANG, LILIN

Inventor name: BOT, ADRIAN

Inventor name: PHILLIPS, BILL

Inventor name: SMITH, DAN

A4 Supplementary search report drawn up and despatched

Effective date: 20090715

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091014